PLN 32.2
(1.58%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 79.91 Million PLN | 80.58% |
2022 | 45.43 Million PLN | 29.99% |
2021 | 34.95 Million PLN | 186.12% |
2020 | 12.21 Million PLN | 55.52% |
2019 | 7.85 Million PLN | 89.46% |
2018 | 4.14 Million PLN | 709.77% |
2017 | 512 Thousand PLN | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 12.7 Million PLN | -29.92% |
2024 Q2 | 13.08 Million PLN | 6.68% |
2023 Q4 | 18.13 Million PLN | 4.68% |
2023 Q1 | 16.56 Million PLN | 26.87% |
2023 Q3 | 17.32 Million PLN | -46.28% |
2023 FY | 82.04 Million PLN | 80.58% |
2023 Q2 | 32.24 Million PLN | 94.63% |
2022 Q2 | 10.88 Million PLN | -6.22% |
2022 FY | 45.43 Million PLN | 29.99% |
2022 Q4 | 13.05 Million PLN | 32.08% |
2022 Q3 | 9.88 Million PLN | -9.18% |
2022 Q1 | 11.6 Million PLN | -1.89% |
2021 Q2 | 6.81 Million PLN | 20.88% |
2021 Q4 | 11.83 Million PLN | 10.87% |
2021 Q3 | 10.67 Million PLN | 56.57% |
2021 FY | 34.95 Million PLN | 186.12% |
2021 Q1 | 5.63 Million PLN | 276.37% |
2020 FY | 12.21 Million PLN | 55.52% |
2020 Q3 | 6.23 Million PLN | 0.0% |
2020 Q4 | 1.49 Million PLN | -75.96% |
2019 FY | 7.85 Million PLN | 89.46% |
2018 FY | 4.14 Million PLN | 709.77% |
2017 FY | 512 Thousand PLN | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Bioceltix S.A. | 15.38 Million PLN | -419.455% |
BIOTON S.A. | 57.55 Million PLN | -38.846% |
Mabion S.A. | 59.52 Million PLN | -34.265% |
Molecure S.A. | 31.73 Million PLN | -151.863% |
NanoGroup S.A. | 7.82 Million PLN | -921.088% |
Pharmena S.A. | -32.76 Million PLN | 343.91% |
Poltreg S.A. | 15.47 Million PLN | -416.426% |
Pure Biologics Spólka Akcyjna | 29.14 Million PLN | -174.214% |
Ryvu Therapeutics S.A. | 4.73 Million PLN | -1586.724% |
Synthaverse S.A. | 26.35 Million PLN | -203.244% |
Urteste S.A. | 5.96 Million PLN | -1239.092% |